If there is a textbook formula for when to conduct a public offering, Pharmion Corp. might have followed it to the letter on Thursday, raising $220.8 million just six weeks after receiving FDA approval for Vidaza. (BioWorld Today)
About seven years since its inception, Vectura Ltd. dipped its feet into public waters on Friday, conducting an initial public offering on London's Alternative Investment Market to raise £20 million (US$36.4 million). (BioWorld Today)
Just as researchers geared up to start a second pivotal trial of iseganan in ventilator-associated pneumonia (VAP), the floor fell from beneath IntraBiotics Pharmaceuticals Inc. Wednesday. (BioWorld Today)
In a deal potentially worth $384 million for Vertex Pharmaceuticals Inc., the company entered a global collaboration with Merck & Co. Inc. to develop and commercialize the former's lead aurora kinase inhibitor, VX-680. (BioWorld Today)
